Rockwell Medical, Inc. shares have received a Mean Price Target of $17.83. According to the rating issued from 6 Wall Street Analysts, the High Price Target is seen at $27 while the Lower end of the Price Target is seen at $4. The Median Price Target is calculated at $17.5.

The stock has received coverage from different analysts. Oppenheimer initiates coverage on Rockwell Medical, Inc. (NASDAQ:RMTI) In a research note issued to the investors, the brokerage major a price-target of $24 per share.The shares have been rated Outperform.

The company has received recommendation from many analysts. 3 analysts have rated the company as a strong buy. 2 analysts have suggested buy for the company.1 analyst has also rated it as a strong sell.

Rockwell Medical, Inc. (NASDAQ:RMTI) rose 4.41% or 0.53 points on Monday and made its way into the gainers of the day. After trading began at $12.15 the stock was seen hitting $12.6 as a peak level and $11.78 as the lowest level. The stock ended up at $12.55. The daily volume was measured at 917,011 shares. The 52-week high of the share price is $12.47 and the 52-week low is $8.095. The company has a market cap of $630 million.

Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.

...